Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates
Company Expects to Submit an NDA for Roluperidone, Subject to FDA Guidance, in the Third Quarter of 2022WALTHAM, Mass., May...
Day: May 4, 2022
Sarepta Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare...
Dyve Biosciences to Present at the UBS Global Healthcare Conference
CAMARILLO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal...
Premier Health Announces the Appointment of Giovanni Garay as Ontario General Manager
MONTREAL, May 04, 2022 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a...
Gracell Biotechnologies to Participate in Three Investor Conferences in May
SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 04, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”),...
TRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022
SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the...
Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital
Upfront payment of $100 million, an additional $160 million available upon FDA approval of vonoprazan for treatment of erosive esophagitis...
IN8bio to Present at May Investor and Scientific Conferences
NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery...
CRISPR Therapeutics to Present at the 2022 Bank of America Healthcare Conference
ZUG, Switzerland and CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on...
Rhythm Pharmaceuticals to Present at BofA Securities 2022 Healthcare Conference
BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the...
Immutep Presents New and Significant Data from the AIPAC Study
Statistically significant increase in innate and adaptive immune response biomarkers (monocyte and CD8 T cell counts and serum CXCL10 levels)...
Dentsply Sirona opens the gateway to a new digital universe with cloud-based solution DS Core
Today’s virtual global event sets the stage for the launch of DS Core – a cloud-based solution powered by the...
RAPT Therapeutics Expands Leadership Team with Multiple Key Hires
SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company...
Allena Pharmaceuticals Announces $2.8 Million Registered Direct Offering
NEWTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing...
Aspargo Acquires Bandol® Sildenafil Spray, Currently Marketed In Spain
Immediate revenue and expansion of global footprint Acquisition transforms Aspargo into a revenue producing company European market entry positions Aspargo...
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 04, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy...
Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors
LONDON, May 04, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell...
Stryker declares a $0.695 per share quarterly dividend
Kalamazoo, May 04, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend...
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2022
Initiated EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis Described new understanding of α4β7-expressing immune cells and...
AviadoBio to Present Pre-clinical Data on its Gene Therapy Candidate for Frontotemporal Dementia at ASGCT 2022
AviadoBio to Present Pre-clinical Data on its Gene Therapy Candidate for Frontotemporal Dementia at ASGCT 2022 Intrathalamic delivery of AVB-101...
